Assessment of the Association Between Metabolic Associated Fatty Liver Disease (MFLD) and Biopsy Proved Cases of GN

Assessment of the Association Between Metabolic Associated Fatty Liver Disease MFLD and Glomerulonephritis

Fatty liver disease is a global health concern with a prevalence of about 25% amongst United States. Its increased prevalence is attributed to increase in patients with obesity and metabolic syndrome (1). Diabetes mellitus (DM),obesity, hyperinsulinemia are predisposing factors for fatty liver disease(2). Glomerulonephritis (GN), a complex syndrome encompassing a variety of individual disorders, is associated with significant morbidity and mortality(3). Given its association with hyperlipidaemia, metabolic syndrome and long-term use of steroid there is concern that patients with GN may be at increased risk of fatty liver disease Patients with NS are frequently found to have fatty liver disease even when adjusting for common risk factors(1). It is known that obesity is an independent risk factor for CKD and it is associated with the development of proteinuria and pathologic findings of podocyte hypertrophy and focal segmental glomerular sclerosis even in the absence of diabetes and hypertension . In addition, studies have shown that obesity as well as metabolic syndrome is a strong predictor of the development of fatty liver disease (4) . Hence, clinicians should maintain a high index of suspicion regarding presence of NAFLD in patients with NS

Inclusion Criteria:

• Patients with biopsy proven primary glomerulonephritis.
• Age >18 years

Exclusion Criteria:

1. Patients with e-GFR<60ml/min/1.73m2
2. Patients with secondary glomerulonephritis
3. Patients with body mass index >35 kg/m2
4. Patients known to be diabetic.
5. Patients known to be hypertensive.
6. Patients with HCV or HBV infection either acute or chronic
7. Patients with acute hepatitis whatever the aetiology
8. Patients with autoimmune diseases